Survival Benefit Seen With Triple Therapy for Severe COVID-19
Compared with dual therapy, significant survival benefit seen with dexamethasone, remdesivir, and baricitinib but no change in length of stay
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.